抗体偶联药物治疗尿路上皮癌的研究进展

Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

摘要:

尿路上皮癌（urothelial carcinoma，UC）是泌尿系统常见的恶性肿瘤，在手术、化疗和免疫治疗等多种治疗措施下，仍有部分患者经历疾病复发、转移，预后不佳。抗体偶联药物（antibody-drug conjugate，ADC）兼有抗体药物的靶向性和化疗药物的细胞毒性，是近年来癌症个体化精准治疗的研究热点，成为这些患者新的选择。目前ADC治疗UC相关临床试验成果颇丰，靶向Nectin-4的Enfortomab Vedotin、靶向TROP-2的Sacituzumab Govitecan和靶向HER-2的Disitamab Vedotin已获批应用于临床，针对其他靶点的新型ADC也开始崭露头角。本文拟对最近的研究进展进行综述。

Abstract:

Urothelial carcinoma（UC） is a common malignancy of the urological system. Under a variety of treatment measures，such as surgery，chemotherapy and immunotherapy，some patients still suffer disease recurrence and metastasis，leading to poor prognosis. Antibody-drug conjugate（ADC） combining the targeting of antibody drugs and the cytotoxicity of chemotherapeutic drugs，has recently become a research hotspot for individualized precision treatment of cancer and a new choice for these patients. At present，the clinical trials related to ADC in the treatment of UC have achieved fruitful results. Enfortomab Vedotin targeting Nectin-4，Sacituzumab Govitecan targeting TROP-2，and Disitamab Vedotin targeting HER-2 have been approved to be applied in clinical practice，and new ADCs for other targets have also begun to emerge. This article intends to review the latest research in this field.